PubRank

K A Freedberg

Author PubWeight™ 47.21‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Trillion virion delay: time from testing positive for HIV to presentation for primary care. Arch Intern Med 1998 3.45
2 Sexual ethics. Disclosure of HIV-positive status to partners. Arch Intern Med 1998 2.67
3 Understanding delay to medical care for HIV infection: the long-term non-presenter. AIDS 2001 2.65
4 Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness. Ann Intern Med 2001 2.47
5 The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA 1999 2.35
6 Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men. Am J Med 2000 2.21
7 Impact of opportunistic diseases on chronic mortality in HIV-infected adults in Côte d'Ivoire. S Afr Med J 2006 1.67
8 Validity and responsiveness of the euroqol as a measure of health-related quality of life in people enrolled in an AIDS clinical trial. Qual Life Res 2002 1.60
9 Positive Epstein-Barr virus heterophile antibody tests in patients with primary human immunodeficiency virus infection. Am J Med 2001 1.43
10 Late presentation for HIV care in central Haiti: factors limiting access to care. AIDS Care 2007 1.30
11 A model clinic for the initial evaluation and establishment of primary care for persons infected with human immunodeficiency virus. Arch Intern Med 1995 1.27
12 Linkage to care following community-based mobile HIV testing compared with clinic-based testing in Umlazi Township, Durban, South Africa. HIV Med 2013 1.25
13 The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. Ann Intern Med 1999 1.22
14 Screening for acute HIV infection in South Africa: finding acute and chronic disease. HIV Med 2011 1.19
15 Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts. Int J Epidemiol 2001 1.15
16 Factors associated with initiation of primary medical care for HIV-infected persons. Am J Med 1994 1.12
17 The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. J Viral Hepat 2010 1.11
18 Routine, voluntary HIV testing in Durban, South Africa: correlates of HIV infection. HIV Med 2008 1.07
19 Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost-effectiveness analysis. Clin Infect Dis 2002 1.03
20 A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection. Med Decis Making 1998 0.99
21 Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. Am J Med 2001 0.97
22 Investigation of primary human immunodeficiency virus infection in patients who test positive for heterophile antibody. Clin Infect Dis 2001 0.96
23 The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach. HIV Med 2007 0.92
24 Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA. HIV Med 2011 0.89
25 AIDS among the homeless of Boston: a cohort study. J Acquir Immune Defic Syndr Hum Retrovirol 1995 0.88
26 Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. Am J Public Health 2001 0.87
27 The cost-effectiveness of fluconazole prophylaxis against primary systemic fungal infections in AIDS patients. Med Decis Making 1997 0.87
28 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: an overview. USPHS/IDSA Prevention of Opportunistic Infections Working Group. Clin Infect Dis 1995 0.86
29 Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus. Clin Infect Dis 2001 0.86
30 Performance measures for guidelines on preventing opportunistic infections in patients infected with human immunodeficiency virus. Clin Infect Dis 2000 0.83
31 Late diagnosis of HIV infection at two academic medical centers: 1994-2004. AIDS Care 2008 0.82
32 Dermatologic manifestations in HIV-infected patients: a primary care perspective. Mayo Clin Proc 1999 0.82
33 The cost-effectiveness of liver biopsy in rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1995 0.80
34 Management of childhood lead poisoning: clinical impact and cost-effectiveness. Med Decis Making 1995 0.79
35 Screening for childhood lead poisoning: a cost-minimization analysis. Am J Public Health 1994 0.78
36 An overview of the 1999 US Public Health Service/Infectious Diseases Society of America guidelines for preventing opportunistic infections in human immunodeficiency virus-infected persons. Clin Infect Dis 2000 0.77
37 The cost-effectiveness of prophylaxis for Mycobacterium avium complex in AIDS. Int J Technol Assess Health Care 1999 0.75
38 Cost-effectiveness of stress-echocardiography. Cardiol Clin 1999 0.75
39 Antischizophrenic drugs: differential plasma protein binding and therapeutic activity. Life Sci 1979 0.75
40 Cost-effectiveness of prenatal screening for postpartum thyroiditis. J Womens Health Gend Based Med 2001 0.75
41 Improving medical residents' attitudes toward HIV-infected persons through training in an HIV staging and triage clinic. Acad Med 1994 0.75
42 Are European-specific guidelines needed for prevention of opportunistic infections in HIV-1? Lancet 1999 0.75
43 Clinical and economic aspects of prophylaxis and treatment of Pneumocystis carinii pneumonia. Pharmacoeconomics 1995 0.75